Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 580796, 6 pages
http://dx.doi.org/10.1155/2013/580796
Clinical Study

Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients

1Centro A.M. e A. Migliavacca, First Division of Gastroenterology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, Università degli Studi di Milano, Via F. Sforza 35, 20122 Milano, Italy
2Division of Hepatology, Ospedale San Giuseppe IRCCS MultiMedica, Università degli Studi di Milano, 20122 Milano, Italy
3Division of Internal Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, 20122 Milano, Italy
4Istituto Nazionale Genetica Molecolare Milano (INGM), 20122 Milano, Italy

Received 26 April 2013; Accepted 19 June 2013

Academic Editor: Kusum Kharbanda

Copyright © 2013 Alessio Aghemo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. European Association for the Study of the Liver, “EASL Clinical Practice Guidelines: management of hepatitis C virus infection,” Journal of Hepatology, vol. 55, pp. 245–264, 2011. View at Google Scholar
  2. E. Degasperi and A. Aghemo, “Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C,” Journal of Viral Hepatitis, vol. 19, no. 1, pp. 3–6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. I. M. Jacobson, J. G. McHutchison, G. Dusheiko et al., “Telaprevir for previously untreated chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 364, no. 25, pp. 2405–2416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Poordad, J. McCone Jr., B. R. Bacon et al., “Boceprevir for untreated chronic HCV genotype 1 infection,” The New England Journal of Medicine, vol. 364, no. 13, pp. 1195–1206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. G. Ghany, D. R. Nelson, D. B. Strader, D. L. Thomas, and L. B. Seeff, “An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases,” Hepatology, vol. 54, no. 4, pp. 1433–1444, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Aghemo, E. Degasperi, and M. Colombo, “Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials,” Digestive and Liver Disease, vol. 45, no. 1, pp. 1–7, 2013. View at Google Scholar
  7. C. Cammà, S. Petta, M. Enea et al., “Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C,” Hepatology, vol. 56, no. 3, pp. 850–860, 2012. View at Google Scholar
  8. S. Liu, L. E. Cipriano, M. Holodniy, D. K. Owens, and J. D. Goldhaber-Fiebert, “New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis,” Annals of Internal Medicine, vol. 156, no. 4, pp. 279–290, 2012. View at Google Scholar · View at Scopus
  9. D. Ge, J. Fellay, A. J. Thompson et al., “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance,” Nature, vol. 461, no. 7262, pp. 399–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. J. Thompson, A. J. Muir, M. S. Sulkowski et al., “Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus,” Gastroenterology, vol. 139, no. 1, pp. 120.e18–129.e18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. F. Gellad, S. Naggie, S. D. Reed et al., “The cost-effectiveness of a telaprevir inclusive regimen as initial therapy for genotype 1 hepatitis C infection in individuals with the CC IL28B polymorphism,” Hepatology, vol. 54, S1, A118, 2011. View at Google Scholar
  12. P. Ramachandran, A. Fraser, K. Agarwal et al., “UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 6, pp. 647–662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Aghemo, M. G. Rumi, S. Monico et al., “The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype,” Antiviral Therapy, vol. 14, no. 4, pp. 577–584, 2009. View at Google Scholar · View at Scopus
  14. M. G. Rumi, A. Aghemo, G. M. Prati et al., “Randomized Study of peginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C,” Gastroenterology, vol. 138, no. 1, pp. 108–115, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Valenti, M. Rumi, E. Galmozzi et al., “Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C,” Hepatology, vol. 53, no. 3, pp. 791–799, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Marabita, A. Aghemo, S. de Nicola et al., “Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection,” Hepatology, vol. 54, no. 4, pp. 1127–1134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. P. J. Clark, A. Aghemo, E. Degasperi et al., “Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy,” Journal of Viral Hepatitis, 2013. View at Publisher · View at Google Scholar
  18. E. Galmozzi, B. D. Menico, R. Rametta et al., “A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype,” Journal of Viral Hepatitis, vol. 18, no. 9, pp. 628–630, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. B. M. Motta, P. Dongiovanni, S. Fargion, and L. Valenti, “T-ARMS-PCR for the evaluation of rs12979860 IL28B genotype: an optimized protocol,” Journal of Viral Hepatitis, vol. 19, no. 3, article 228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Mangia, A. J. Thompson, R. Santoro et al., “An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response,” Gastroenterology, vol. 139, no. 3, pp. 821.e1–827.e1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. De Nicola, A. Aghemo, M. Grazia Rumi et al., “Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4,” Hepatology, vol. 55, no. 2, pp. 336–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. T.-M. Scherzer, A. F. Stättermayer, M. Strasser et al., “Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin,” Hepatology, vol. 54, no. 5, pp. 1518–1526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. R. D'Ambrosio, A. Aghemo, M. G. Rumi et al., “A morphometric and immunohistochemical study to assess the benefit of an svr in hcv cirrhotic patients,” Hepatology, vol. 56, no. 2, pp. 532–543, 2012. View at Google Scholar
  24. G. M. Prati, A. Aghemo, M. G. Rumi et al., “Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis,” Journal of Hepatology, vol. 56, no. 2, pp. 341–347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Sarrazin, T. Berg, M. Cornberg et al., “Expert opinion on Boceprevir- and Telaprevir-based triple therapies of chronic hepatitis C,” Zeitschrift fur Gastroenterologie, vol. 50, no. 1, pp. 57–72, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. “AISF position paper on the use of triple therapy with a protease inhibitor in patients with chronic hepatitis C genotype 1,” 2012, http://www.webaisf.org/media/14647/position-paper-definitivo-26-01-12.pdf.
  27. S. Bruno and A. Mangia, “Futility of antiviral treatments for hepatitis C: an evolving concept entering the direct antiviral agents era,” Digestive and Liver Disease, vol. 45, no. 5, pp. 356–361, 2013. View at Google Scholar
  28. T. Awad, K. Thorlund, G. Hauser, D. Stimac, M. Mabrouk, and C. Gluud, “Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2B in chronic hepatitis C: systematic review of randomized trials,” Hepatology, vol. 51, no. 4, pp. 1176–1184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Sarrazin, M. L. Shiffman, S. J. Hadziyannis et al., “Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy,” Journal of Hepatology, vol. 52, no. 6, pp. 832–838, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Vermehren, A. Aghemo, S. Susser et al., “Differences in HCV genotype 1 RVR rates among clinical trials in Europe depend on HCV RNA assay sensitivity,” Journal of Hepatology, vol. 56, no. S2, p. S364, 2012. View at Google Scholar
  31. M. Fraquelli, C. Rigamonti, G. Casazza et al., “Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease,” Gut, vol. 56, no. 7, pp. 968–973, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Castera, “Noninvasive methods to assess liver disease in patients with hepatitis B or C,” Gastroenterology, vol. 142, no. 6, pp. 1293.e4–1302.e4, 2012. View at Publisher · View at Google Scholar · View at Scopus